Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology.

With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders.

For more information, please visit: www.daiichisankyo.com.

Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is a member of the Daiichi Sankyo Group. To learn more about Daiichi Sankyo, Inc., please visit www.dsi.com.

211 Mt. Airy Road
Basking Ridge, NJ 07920

Tel: (908) 992-6400

Visit website

NEWS

Pictured: Gilead sign in front of tree_JOSH EDELSO

Drug Development

Gilead, Merck, Daiichi Sankyo and more Preview ESMO Presentations

Gilead, Merck, Daiichi Sankyo, HUTCHMED and BMS previewed data to be presented at the European Society for Medical Oncology Congress 2022, taking place Sept. 9-13.

September 6, 2022

5 min read

Alex Keown

Drug Development

Gilead’s Trodelvy Gives Enhertu a Run for its Money in Metastatic Breast Cancer

Weeks after AstraZeneca and Daiichi Sankyo were able to move the bar in the treatment of metastatic breast cancer with Enhertu, Gilead is answering that challenge with Trodelvy.

August 16, 2022

3 min read

Alex Keown

Policy

Seagen Loses Patent Battle against Daiichi Sankyo as Merck Waits in the Wings

As the biotech world awaits the announcement of Merck’s anticipated buyout of Seagen, an arbitrator came down on the side of Daiichi Sankyo in a patent battle against the Seattle-based biotech.

August 15, 2022

3 min read

Mark Terry

FDA

FDA Review: Bayer, Daiichi Sankyo, AstraZeneca and More

Daiichi Sankyo and AstraZeneca report another first-in-class approval for Enhertu, Bayer snags an sNDA in metastatic hormone-sensitive prostate cancer and Merck faces contamination challenges with Januvia.

August 12, 2022

3 min read

Mark Terry

Drug Development

AstraZeneca and Daiichi Sankyo’s Enhertu Racks up Another Clinical Win in Breast Cancer (Updated)

AstraZeneca and Daiichi Sankyo’s Enhertu has been approved by the FDA as the first HER2-directed medicine for the treatment of patients with HER2-mutant metastatic NSCLC.

August 12, 2022

4 min read

Alex Keown

Drug Development

Verona, Daiichi Sankyo, AstraZeneca and Kodiak Score Big Wins in Key Diseases

The week started off with a clinical bang for Verona Pharma, Kodiak, AstraZeneca and Daiichi Sankyo with wins in COPD, lung cancer and macular edema respectively.

August 9, 2022

3 min read

Vanessa Doctor, RN

Drug Development

“Practice-Changing” Trial Introduces New Standard of Care for Breast Cancer Patients

The DESTINY-Breast04 trial introduces a new option for breast cancer diagnosis – HER2-low. The trial data received a standing ovation from thousands of oncologists at this year’s ASCO meeting.

July 27, 2022

6 min read

Kaley Lefevre

Drug Development

FDA Hands Out Regulatory Nods to Novartis, AstraZeneca, HOOKIPA

Daiichi-Sankyo and AstraZeneca’s sBLA for HER2 directed Enhertu accepted by FDA. Novartis gets BLA acceptance for MS biosimilar. HOOKIPA’s IND for prostate cancer immunotherapy candidate accepted

July 25, 2022

4 min read

Tristan Manalac

Policy

Battle of the Patents: Daiichi Sankyo, Seagen, Alnylam, CureVac, Pfizer, BioNTech & Moderna

The LPN technology used in the mRNA COVID-19 vaccines has been the target of numerous patent challenges. Here’s a look at recent biopharma patent disputes.

July 20, 2022

3 min read

Mark Terry

JOBS